articleThe Lancet OncologyMay 20, 2019Closed access

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

HWHoward WestMMMichael McCleodMHMaen HusseinAMAlessandro MorabitoARAchim Rittmeyer

Sarah Cannon · Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · +14 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,663
total citations
FWCI
85.26
Percentile
100%
References
22
Citations per year

Authors

20

Topics & keywords

Topics
Keywords
  • Carboplatin
  • Medicine
  • Paclitaxel
  • Atezolizumab
  • Chemotherapy
  • Oncology
  • Nab-paclitaxel
  • Open label
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding